Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
View stock

Stock highlights

Stock comparison highlights
Stock name
iSpecimenAbbVie
Last price
$0.70$294.45
Currency
USD
USD
$1.8M$521B
-50.79
-$21.95$5.81
1.630.19
0$6.83
02.35%
Sector
HealthHealth
Employees
757,000
Ticker
$ISPC$ABBV
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $ISPC or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.